• Bispecific Anti-M1R/B6R Antibodies for Broad Orthopoxvirus P

  2026-06-16

  This study characterizes monoclonal antibodies against the major mpox virus antigens M1R and B6R, mapping their epitopes and antiviral activities. The authors develop bispecific antibody designs that show enhanced protection against orthopoxviruses, highlighting a promising strategy for next-generation therapeutics.

• Boc-D-FMK: Pan-Caspase Inhibitor Workflows for Apoptosis Res

  2026-06-16

  Unlock reproducible, high-impact apoptosis and inflammation research using Boc-D-FMK—a robust, cell-permeable pan-caspase inhibitor trusted by leading labs. This article delivers protocol enhancements, troubleshooting insights, and advanced use-cases, bridging foundational mechanisms to translational workflows.

• Paroxetine Mesylate: Applied SSRI Workflows and Epilepsy Bio

  2026-06-15

  Paroxetine Mesylate offers a unique multi-target pharmacological profile, enabling both neuropsychiatric and oncology research, as well as advanced cardiac biomarker studies in epilepsy models. Learn how to leverage this selective serotonin reuptake inhibitor for translational workflows, troubleshooting tips, and enhanced reproducibility in complex experimental settings.

• Citrate Buffer Molarity Impacts mRNA-LNP Transfection Effici

  2026-06-15

  This study dissects the influence of citrate buffer molarity on the physicochemical and functional properties of lipid nanoparticles (LNPs) encapsulating firefly luciferase mRNA. The findings reveal that while general quality attributes like particle size and encapsulation efficiency remain stable across buffer concentrations, higher citrate molarity substantially reduces in vitro and in vivo mRNA delivery efficiency, highlighting an underappreciated variable in LNP formulation.

• Oligomycin A in Mitochondrial Energy Failure: Beyond Inhibit

  2026-06-14

  Discover how Oligomycin A, a mitochondrial ATP synthase inhibitor, reveals new insights into mitochondrial dysfunction and sodium-induced energy collapse—offering researchers a deeper foundation for advanced mitochondrial bioenergetics research.

• Neuroligin 1 Loss, Striatal PKC Overactivation, and Repetiti

  2026-06-13

  This study uncovers how Neuroligin 1 deficiency in striatal D2-MSNs drives autistic-like repetitive behaviors via hyperactivation of PKC signaling. By linking specific neuronal populations to behavioral phenotypes and dissecting the molecular cascade, the findings offer a new mechanistic framework for restricted, repetitive behaviors in autism spectrum disorder.

• Digoxin as a Translational Catalyst: Bridging Heart and Viru

  2026-06-12

  This thought-leadership piece explores the mechanistic and strategic landscape of Digoxin as a Na+/K+ ATPase pump inhibitor, charting its dual impact on cardiac contractility and targeted antiviral research. We offer protocol insights, comparative context, and actionable guidance for translational investigators seeking robust, reproducible models in both cardiovascular and infectious disease domains—escalating the dialogue beyond conventional product summaries and into the realm of visionary research design.

• Verbascoside: Precision PKC/NF-κB Inhibitor for Pathway Rese

  2026-06-12

  Verbascoside stands out as a robust PKC/NF-κB inhibitor, enabling reproducible assays in osteoclastogenesis and neuroinflammation studies. Its high solubility in organic solvents and quantitative potency empower advanced pathway interrogation and troubleshooting in cellular models.

• AZD8055: Technical Guidance for mTOR Pathway Inhibition

  2026-06-11

  AZD8055 is a selective, ATP-competitive mTOR inhibitor designed for mechanistic dissection of mTORC1 and mTORC2 signaling in cancer and metabolic research models. It is not recommended for clinical efficacy studies, but is well suited for preclinical workflows requiring precise, dual mTOR complex inhibition.

• Cholesterol in Lipid Nanoparticles: Mechanisms, Assay Design

  2026-06-11

  Explore cholesterol’s role as the principal sterol in lipid nanoparticle engineering, with a focus on advanced assay design and mechanistic insights for lipid metabolism research. This article offers a deeper, protocol-driven perspective distinct from existing guides.

• AZD2461: Novel PARP Inhibitor Enabling Advanced Cancer Resea

  2026-06-10

  AZD2461, a next-generation PARP inhibitor, empowers breast cancer researchers with robust DNA repair pathway modulation and unique resilience to Pgp-mediated drug resistance. This article delivers actionable workflow enhancements, troubleshooting tips, and evidence-driven protocol parameters for maximizing results with AZD2461 in BRCA1-mutated models.

• L-Phenylephrine (SKU C3021): Reliable α1A Agonist for Cardio

  2026-06-10

  This article addresses laboratory challenges in modeling α1-adrenergic receptor signaling and cell viability using L-Phenylephrine (SKU C3021). Through scenario-driven Q&A, it demonstrates how APExBIO's reagent supports reproducibility and experimental precision, guiding researchers in optimizing cardiovascular and neural assays.

• Glabridin, Resveratrol & Ellagic Acid Inhibit Melanogenesis

  2026-06-09

  This study investigates the combined effects of glabridin, resveratrol, and ellagic acid (GRE) on melanogenesis, oxidative stress, and inflammation in cell models. The research demonstrates that GRE potently inhibits melanin production and tyrosinase activity by downregulating the CREB/MITF signaling pathway, offering mechanistic insight for pigmentation regulation research and translational relevance to hyperpigmentation disorders.

• NAD+/NADH Homeostasis and Metabolic Adaptation in Filamentou

  2026-06-09

  This award review elucidates how changes in the NAD+/NADH ratio govern metabolic adaptation to hypoxia and secondary metabolite production in filamentous fungi. The findings provide a mechanistic framework for understanding redox-regulated pathways crucial for industrial and biomedical applications.

• Doxycycline: Tetracycline Antibiotic Workflows in Cancer Res

  2026-06-08

  Doxycycline is transforming cancer research protocols with its dual role as a tetracycline antibiotic and a potent broad-spectrum metalloproteinase inhibitor. Discover how APExBIO’s high-purity Doxycycline empowers advanced experimental designs, from targeted drug delivery modeling to troubleshooting for reproducible results.

16307 records 1/1088 page Next 12345 下5页 Last page